drugset / Trial / NCT01544998
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
Phase 1/2
Completed
43 enrolled
Mayo Clinic
National Center for Research Resources (NCRR) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverTriple-blindPrevention
Summary
This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: * The pumping function of the heart * Kidney function * Hormonal function (levels of different hormones in your blood) in persons with lower pumping function of their heart.
Timeline
- Start
- 2012-02
- Primary completion
- 2013-08
- Completion
- 2014-08
Publications
- Wan SH, McKie PM, Slusser JP, Burnett JC Jr, Hodge DO, Chen HH. Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiol Rep. 2021 Aug;9(16):e14974. doi: 10.14814/phy2.14974.
- Wan SH, Torres-Courchoud I, McKie PM, Slusser JP, Redfield MM, Burnett JC Jr, Hodge DO, Chen HH. Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic Transl Sci. 2019 Dec 23;4(8):962-972. doi: 10.1016/j.jacbts.2019.08.008. eCollection 2019 Dec.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nesiritide | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Tadalafil | Small molecule | 5 mg | Oral |